Wemurafenib i dabrafenib obniżają poziom RIPK4

Vemurafenib and Dabrafenib Downregulates RIPK4 Level

RIPK4 kinase has oncogenic functions in melanoma and shows high similarity to BRAF protein, making this kinase sensitive to the BRAF inhibitors vemurafenib and dabrafenib. Molecular docking was used to dock BRAF inhibitors into the ATP-binding sites of RIPK4. The determined affinity energy for the inhibitors is −9.4 kcal/mol for dabrafenib and −9.1 kcal/mol for vemurafenib. Both are lower than those of the ATP molecule, which is −6.8 kcal/mol.

 

 

Madej E, Brożyna AA, Adamczyk A, Wronski N, Harazin-Lechowska A, Muzyk A, Makuch K, Markiewicz M, Wolnicka-Glubisz A, Vemurafenib and Dabrafenib Downregulates RIPK4 Level. Cancers, 2023, 15(3), 918.